Clinical trials: Cancer, Gastrointestinal
Solid Tumor, Adult, Colorectal Cancer
A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression
The goal of this study is to test autologous logic-gated Tmod™ CAR T-cell products in subjects with solid tumors including colorectal cancer (CRC), pancreatic cancer (PANC), non-small cell lung cancer (NSCLC), ovarian cancer…
- Conditions
- Solid Tumor, Adult, Colorectal Cancer, NSCLC, Non Small Cell Lung Cancer
- Trial name
- EVEREST-2 (NCT06051695)
- Testing
- A2B694, A2B543, xT CDx with HLA-LOH Assay
- Where
- 12 sites in United States
- Volunteers
- 474 people
- Sponsor
- A2 Biotherapeutics Inc.
Pancreatic Cancer
Combination of Icotinib and Gemcitabine as First-line Treatment in Pancreatic Cancer
Research Hypothesis: icotinib administered in combination with gemcitabine has an acceptable safety profile in subjects with locally advanced, unresectable or metastatic pancreatic adenocarcinoma.The primary objective is to…
- Trial name
- NCT02278458
- Testing
- icotinib, Gemcitabine
- Where
- 3 sites in China
- Volunteers
- 24 people
- Sponsor
- Betta Pharmaceuticals Co., Ltd.
Pancreatic Ductal Adenocarcinoma, Non-Small Cell Lung Cancer
Phase I Study of [177Lu]Lu-DFC413 in Patients With Solid Tumors
The purpose of this study is to evaluate the safety, tolerability, dosimetry and preliminary efficacy of [177Lu]Lu-DFC413 and safety and imaging properties of [68Ga]Ga-NNS309 in patients aged ≥ 18 years with solid tumors
- Conditions
- Pancreatic Ductal Adenocarcinoma, Non-Small Cell Lung Cancer, HR+/HER2- Ductal and Lobular Breast Cancer, Triple Negative Breast Cancer
- Trial name
- NCT07261631
- Testing
- 68Ga-NNS309, 177Lu-DFC413
- Where
- 9 sites in United States, Canada and 5 more
- Volunteers
- 180 people
- Sponsor
- Novartis Pharmaceuticals
Hepatocellular Carcinoma, Advanced Hepatocellular Carcinoma
A Safety and Efficacy Study of Multiple Tyrosine Kinase Inhibitor Drug (ETN101) in Advanced Hepatocellular Carcinoma
ETN101 is a multiple tyrosine kinase inhibitor (mTKI) targeting fms-like tyrosine kinase 3 (FLT3), receptor tyrosine kinase (KIT), vascular endothelial growth factor receptor 2 (VEGFR2), and platelet-derived growth factor…
- Conditions
- Hepatocellular Carcinoma, Advanced Hepatocellular Carcinoma, Liver Cancer
- Trial name
- NCT06326502
- Testing
- ETN101
- Where
- 2 sites in South Korea
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Etnova Therapeutics Corp.
Advanced Solid Tumor, Gynecologic Cancer
A Study of PY314 in Subjects With Advanced Solid Tumors
This is an open-label, multicenter, first in human, Phase 1a/1b study of PY314 in subjects with locally advanced (unresectable) and/or metastatic solid tumors that are refractory or relapsed to standard of care (including…
- Conditions
- Advanced Solid Tumor, Gynecologic Cancer, Breast Cancer, Colorectal Cancer
- Trial name
- NCT04691375
- Testing
- PY314, Combination Therapy: PY314 + Pembrolizumab
- Where
- 23 sites in United States
- Volunteers
- 86 people
- Sponsor
- Ikena Oncology
Uterine Cervical Neoplasms, Triple Negative Breast Neoplasms
A Phase II Study of GV20-0251 in Combination With Anti-PD-1 Monoclonal Antibodies in Patients With Unresectable, Locally Advanced, or Metastatic Solid Tumors.
This is a Phase 2 study of GV20-0251 in combination with anti-PD-1 monoclonal antibodies (including tislelizumab and toripalimab) for the treatment of participants with unresectable, locally advanced, or metastatic solid tumors…
- Conditions
- Uterine Cervical Neoplasms, Triple Negative Breast Neoplasms, Prostatic Neoplasms, Squamous Cell Carcinoma of Head and Neck
- Trial name
- NCT07623642
- Testing
- GV20-0251, anti-PD-1 monoclonal antibodies
- Where
- 2 sites in China
- Volunteers
- 227 people
- Sponsor
- GV20 Therapeutics
Colorectal Cancer
Study of Nimotuzumab and Irinotecan in Metastatic Colorectal Cancer
This study will determine if nimotuzumab provides a benefit in this type of cancer when given in combination with irinotecan. The study will test: How long any good effects last. How bad any side effects are.
- Trial name
- NCT00493857
- Testing
- Nimotuzumab Humanized Monoclonal Antibody, Nimotuzumab
- Where
- 12 sites in Canada
- Volunteers
- 100 people
- Sponsor
- YM BioSciences
Solid Tumor Malignancies, Colorectal Carcinoma
Study of CP-383 in Patients With Advanced or Metastatic Solid Tumors
The goal of this clinical trial is to learn if an investigational drug CP-383 works to treat advanced cancer. It will also learn about the safety of CP-383.
- Conditions
- Solid Tumor Malignancies, Colorectal Carcinoma, Small Cell Lung Cancer ( SCLC ), Head and Neck (HNSCC)
- Trial name
- NCT07030257
- Testing
- CP-383
- Where
- 13 sites in United States
- Volunteers
- 150 people
- Sponsor
- Tasca Therapeutics
Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
A Phase 2 Study of Ramucirumab (LY3009806) in Participants With Gastric or Gastroesophageal Junction (GEJ) Cancer
The main purpose of this study was to evaluate the safety and pharmacokinetics of administering various dose regimens of ramucirumab in participants with advanced gastric cancer whose disease has progressed during or following…
- Trial name
- NCT02443883
- Testing
- Ramucirumab
- Where
- 45 sites in United States, Argentina and 10 more
- Volunteers
- 164 people
- Sponsor
- Eli Lilly and Company
Pancreatic Cancer
Trial of DN022150 Versus Chemotherapy in Previously Treated Advanced Pancreatic Cancer With KRAS G12D Mutation
This study plans to enroll participants with previously treated advanced pancreatic cancer and harbor centrally confirmed KRAS G12D mutation.
- Trial name
- NCT07689539
- Testing
- DN022150, Chemotherapy
- Volunteers
- 360 people
- Sponsor
- Jiangxi Kvvit Pharmaceutical Co., Ltd.
Ulcerative Colitis
A Study Comparing the Efficacy and Safety of Etrolizumab to Infliximab in Participants With Moderate to Severe Ulcerative Colitis Who Are Naïve to Tumor Necrosis Factor (TNF) Inhibitors
This is a multicenter, Phase III, randomized, double-blind, double-dummy, parallel-group study to evaluate the safety, efficacy, and tolerability of etrolizumab compared with infliximab in treating participants with moderate to…
- Trial name
- GARDENIA (NCT02136069)
- Testing
- Etrolizumab, Infliximab
- Where
- 119 sites in Austria, Belgium and 18 more
- Volunteers
- 397 people
- Sponsor
- Hoffmann-La Roche
Colorectal Cancer, Pancreatic Cancer
BGT007 Treatment for Recurrent/refractory Gastrointestinal Malignancies
This study is an exploratory research on single arm, open, and improved "3+3" dose escalation. BGT007 will explore two dose groups, namely (Group A: 3.0X10 ^ 8 3 cases, Group B: 6.0X10 ^ 8 3 cases), and receive the same dose…
- Trial name
- NCT06645301
- Testing
- Group A, Group B
- Volunteers
- 15 people
- Sponsor
- BioSyngen Pte Ltd
Peritoneal Carcinomatosis
A Study to Evaluate ONM100, an Intraoperative Fluor Imaging Agent for the Detection of Peri Mets
Peritoneal carcinomatosis (PC) results from the metastasis of a primary cancer of the peritoneum (e.g., appendiceal, ovarian, uterine, colorectal, and gastric cancers) that then disseminates throughout the abdominal cavity.
- Trial name
- NCT04950166
- Testing
- pegsitacianine
- Where
- 5 sites in United States
- Volunteers
- 51 people
- Sponsor
- OncoNano Medicine, Inc.
Cancer, Solid Tumor
Intravenously Administered Pegylated Liposomal Mitomycin-C Lipid-based Prodrug (PROMITIL) in Cancer Patients With Solid Tumors.
This is a Phase I, multi-center, Dose-Escalating, Safety Study of an Intravenously Administered Pegylated Liposomal Mitomycin-C Lipid-based Prodrug (PL-MLP, PROMITIL) in Cancer Patients with Solid Tumors.
- Conditions
- Cancer, Solid Tumor, Metastatic Colorectal Cancer (mCRC)
- Trial name
- NCT01705002
- Testing
- Promitil, Capecitabine, Bevacizumab
- Where
- 4 sites in Israel
- Volunteers
- 88 people
- Sponsor
- Lipomedix Pharmaceuticals Inc.
Liver Cirrhosis
A Study to Compare How Different Medicines (Rosuvastatin, Digoxin, Metformin, and Furosemide) Are Handled by the Body of Healthy People and People With Liver Cirrhosis
This study is open to healthy adults and adults with liver cirrhosis. The purpose of this study is to compare how different medicines are handled by the body in people with and without liver cirrhosis.
- Trial name
- NCT05741372
- Testing
- Rosuvastatin, Digoxin, Metformin hydrochlorid
- Where
- Germany
- Volunteers
- 28 people
- Sponsor
- Boehringer Ingelheim
Locally Advanced or Metastatic Solid Tumors, Colorectal Cancer
A Study of MRG007 (ARR-217) in Patients With Advanced Solid Tumors
This is an open-label, multi-center, phase I study to evaluate the safety, tolerability, efficacy, and pharmacokinetics of MRG007 (ARR-217) in patients with unresectable locally advanced or metastatic solid tumors.
- Conditions
- Locally Advanced or Metastatic Solid Tumors, Colorectal Cancer, Gastric Cancer, Pancreatic Cancer
- Trial name
- NCT07066657
- Testing
- MRG007, MRG007 and Bevacizumab
- Where
- 21 sites in United States, China
- Volunteers
- 572 people
- Sponsor
- ArriVent BioPharma, Inc.
Colon Polyps and Adenomas, Colon Cancer
Polyp Detection With The Peerscope System™
The PeerScope System consists of Peer Medical camera heads, endoscopes, video system, light source and other ancillary equipment.
- Trial name
- NCT01549535
- Testing
- Colonoscopy done with:PeerMedical System and Olympus/Pentax/Fuji colonoscopy system
- Where
- 6 sites in United States, Israel and 1 more
- Volunteers
- 197 people, healthy volunteers welcome
- Sponsor
- PeerMedical Ltd.
Colorectal Cancer, Pancreatic Cancer
Chemical Profiling of Colorectal and Pancreatic Cancers Using Breath Analysis - Feasibility Study
Detection of Colorectal and Pancreatic Cancers Using Breath Analysis - Feasibility Study
- Trial name
- Cancer (NCT05400408)
- Testing
- VOX
- Where
- Israel
- Volunteers
- 250 people, healthy volunteers welcome
- Sponsor
- Scentech Medical Technologies Ltd
Pancreatic Cancer
A Study of Tarceva (Erlotinib) in Combination With Gemcitabine in Unresectable and/or Metastatic Cancer of the Pancreas: Relationship Between Skin Toxicity and Survival
This single arm study will evaluate the relationship between the skin toxicity of Tarceva in combination with gemcitabine, and survival, in patients with advanced and/or metastatic pancreatic cancer.
- Trial name
- NCT00461708
- Testing
- Erlotinib, Gemcitabine
- Where
- 29 sites in Spain
- Volunteers
- 153 people
- Sponsor
- Hoffmann-La Roche
EBV Associated Extranodal NK/T-cell Lymphoma, EBV-Associated GastricCarcinoma or Esophageal AdenoCarcinoma
A Multi-center, Single-arm, Open, Phase I/IIa Clinical Trial to Evaluate the Efficacy and Safety of EBViNT Cell (EBV Specific Autologous CD8+ T Cell) in Patients With Treatment Failed Epstein Barr Virus (EBV)-Positive Malignancies
The present study is a multi-center, single-arm, open, phase I/IIa clinical trial to evaluate the efficacy and safety of EBViNT Cell when administered to patients with Epstein-Barr (EBV) positive malignancies The present study…
- Trial name
- NCT03789617
- Testing
- EBViNT Cell
- Where
- 8 sites in South Korea
- Volunteers
- 72 people
- Sponsor
- Eutilex
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.